重组人脑利钠肽对心力衰竭患者的短期临床疗效分析

Analysis of short-term clinical efficacy of recombinant human brain na-triuretic peptide for heart failure

目的探讨重组人脑利钠肽对心力衰竭患者的短期临床疗效。方法选择心力衰竭患者40例为研究对象,在常规治疗基础上给予重组人脑利钠肽治疗,计算治疗前后液体入量,记录治疗后症状改善情况。结果采用重组人脑利钠肽治疗心力衰竭不同时间点液体负出量比较差异有显著统计学意义(P<0.01)。相关性分析结果显示,在治疗后第1个24 h液体负出量与基础BNP呈负相关关系(r=-0.425,P<0.05)。BNP基础水平越低的患者临床症状体征改善越显著,差异有统计学意义(P<0.01)。结论重组脑利钠肽治疗心力衰竭具有利尿排钠效果,能够有效改善患者临床症状和体征。

Objective To analyze short-term clinical efficacy of recombinant human brain natriuretic peptide for heart failure. Methods Selected 40 cases with heart failure were treated with recombinant human brain natriuretic peptide based on conventional treatment. Fluid intaking before and after treatment was counted, and improvement of symptoms was recorded. Results Minus the amount of fluid before and after showed significant difference（P〈0.01）. Correlation analysis showed that, minus the amount of liquid was negatively correlated with the underlying relationship between BNP in the first 24 h after treatment（r=-0.425,P〈0.05）. Improvement in clinical symptoms and signs of patients with lower basis BNP level was better （P〈0.01）. Conclusion Recombinant human brain natriuretic peptide in treatment of heart failure has natriuresis diuretic effect, and can effectively improve the clinical symptoms and signs.